GET DAILY SIGNALSDanaher (DHR) Shows Resilience in Q3 with Strong EPS Beat and Raised Outlook
Key Takeaways
- Danaher reported third-quarter 2026 revenue of $6.55 billion, up 8.3% year over year and roughly in line with analyst consensus.
- Adjusted diluted earnings per share (EPS) reached $2.11, up 12% from a year earlier and well above the consensus estimate of $1.92.
- Core revenue grew 3.0%, accelerating to 5.5% when excluding the declining respiratory testing business.
- Adjusted operating margin expanded 110 basis points to 29.0%, led by a sharp improvement in the Biotechnology segment.
- Management raised full-year 2026 adjusted EPS guidance to $8.57–$8.62, up from a prior range of $8.45–$8.60.
Why These Results Matter
In my view, Danaher’s third-quarter report provides one of the clearest signals yet on the health of the life sciences and diagnostics markets, particularly bioprocessing demand from pharmaceutical and biotechnology customers. After several quarters of uneven growth, investors have been watching closely for signs that the company’s base business is re-accelerating. The results also mark the first full reporting cycle under new Chief Executive Officer Julie Sawyer Montgomery, who stepped into the role only weeks before the release. With the Masimo acquisition integration still underway and respiratory testing normalizing from elevated levels, this quarter helps distinguish durable core momentum from temporary factors. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Q3 2026 Results in Detail
For the three months ended September 25, 2026, Danaher reported revenue of $6.55 billion, an 8.3% increase from $6.05 billion in the prior-year period. Adjusted diluted EPS came in at $2.11, up 12% from $1.89 a year ago and ahead of the consensus estimate of $1.92. On a generally accepted accounting principles (GAAP) basis, diluted EPS from continuing operations rose 35% to $1.71, and net earnings from continuing operations increased 35% to $1.21 billion.
Core revenue growth was 3.0%, but excluding the normalization of respiratory testing, core growth accelerated to 5.5%. The company generated $1.6 billion in free cash flow during the quarter, a 19% increase from a year earlier.
By segment, Biotechnology revenue was $1.81 billion, up 5.0% on a core basis, with adjusted operating margin expanding 460 basis points to 41.8%. Life Sciences revenue of $1.87 billion grew 4.5% on a core basis. Diagnostics revenue of $2.88 billion rose 17.0% on a reported basis, reflecting the Masimo acquisition, and grew 7.0% on a core basis excluding respiratory testing.
Market Reaction and Investor Sentiment
Market reaction around the release was mixed but leaned positive. Some early trading reports showed shares initially dipping in premarket activity, while others indicated the stock subsequently moved higher as investors weighed the better-than-expected profitability and raised guidance. The key sentiment driver was the gap between Danaher’s $2.11 adjusted EPS and the $1.92 consensus, alongside the upward revision to full-year earnings guidance. Investors also appeared encouraged by the 5.5% core growth excluding respiratory testing, which suggested underlying momentum in bioprocessing and diagnostics even as respiratory revenue remained a drag. The main sources of caution were the continued respiratory headwinds and modest reported core growth at the total-company level.
Outlook and Factors to Watch
Looking ahead, Danaher guided for fourth-quarter core revenue growth of 4% to 5% excluding respiratory testing, with respiratory revenue expected to subtract roughly 150 basis points, resulting in total core growth of approximately 3%. For the full year, the company now expects adjusted EPS of $8.57 to $8.62, implying double-digit growth over 2025.
Investors should monitor whether bioprocessing order trends continue to improve. In the third quarter, biotechnology orders rose mid-teens, with strength in upstream consumables and resins, a signal that could support accelerating growth into 2027. The pace of the Masimo integration in Diagnostics also remains a factor, given its dilutive impact on segment margins during the current integration phase.
Additional areas to watch include the trajectory of respiratory testing revenue, which management expects to reach roughly $1.5 billion for 2026, down about 20% from 2025, and any updates on academic research demand, which has remained below historical levels. Capital allocation, free cash flow conversion, and the new CEO’s strategic priorities are also likely to shape investor expectations in the quarters ahead.
Integrating AI Tools into My Research
One tool I regularly turn to for scanning comparable names and identifying patterns is Tickeron’s AI Screener. It allows me to quickly filter life sciences and diagnostics stocks by fundamentals, technical signals, and performance metrics, which helps put Danaher’s results in broader context without spending hours on manual work. This has become a practical part of my workflow when evaluating earnings beats and guidance changes across the sector.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DHR's Stochastic Oscillator penetrates overbought zone
The Stochastic Oscillator for DHR moved into overbought territory on October 21, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 12 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 41%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on DHR as a result. In 57 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for DHR just turned positive on October 14, 2026. Looking at past instances where DHR's MACD turned positive, the stock continued to rise in 27 of 47 cases over the following month. The odds of a continued upward trend are 57%.
Following a +3.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 174 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 111 of 199 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.127) is normal, around the industry mean (64.450). P/E Ratio (41.465) is within average values for comparable stocks, (2.086). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of industrial instruments and machinery
Industry MedicalSpecialties
Advertisement